Michelle Xia
Michelle Xia | |
|---|---|
| Born | Xia Yu 1966 or 1967 (age 58–59)[1] |
| Nationality | Chinese |
| Known for | Founder, CEO, chairwoman and president of Akeso Biopharma |
Michelle Xia (born 1966 or 1967) is a Chinese billionaire businesswoman, and the founder, CEO, chairwoman and president of the pharmaceutical startup Akeso Biopharma.
Xia was raised in Gansu province, the daughter of two university-educated engineers.[1]
She earned a degree in biochemistry from Sun Yat-sen University in Guangzhou in 1988, and a doctorate in molecular biology and microbiology from Newcastle University in the UK.[1]
Under Xia, Akeso have developed Ivonescimab, which appears to outperform Pembrolizumab (marketed as Keytruda), produced by Merck in the US.[2]
In March 2025, she was included in the Time100 Health 2025.[3]
As of July 2025, Forbes estimates her net worth at US$1.2 billion.[1]
References
- ^ a b c d Dolan, Kerry A. "How This New Biotech Billionaire Outmaneuvered Merck In China". Forbes. Retrieved 24 July 2025.
- ^ Leong, Clarence. "The Chinese CEO Who Believes Her Cancer Drug Can Beat Merck's Bestseller". WSJ. Retrieved 24 July 2025.
- ^ Hu, Charlotte (8 May 2025). "TIME100 Health: Michelle Xia". TIME. Retrieved 24 July 2025.